DEF: Harmony Biosciences Announces Annual Meeting of Stockholders to be Held Virtually on May 15, 2025

Harmony Biosciences will hold its annual meeting of stockholders virtually on May 15, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Harmony Biosciences Holdings, Inc. will hold its 2025 annual meeting of stockholders virtually on May 15, 2025, at 1:00 p.m. Eastern Time.
• The meeting will cover the election of three Class II directors to serve until the 2028 annual meeting, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and any other business that may properly come before the meeting.
• Stockholders of record as of March 17, 2025, are entitled to notice of and to vote at the Annual Meeting.
• The company is primarily furnishing proxy materials electronically, with a Notice of Internet Availability of Proxy Materials mailed around April 4, 2025.
• Stockholders are urged to submit their vote in advance via the Internet, telephone, or mail.
• The board of directors recommends voting for the election of the director nominees and for the ratification of Deloitte & Touche LLP.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information about the upcoming annual meeting. The positive aspects of virtual meetings and cost reduction contribute to a slightly positive sentiment.

Positives

• The virtual meeting format provides expanded access, improved communication, and cost savings for stockholders and Harmony.
• Stockholders can attend, listen, submit questions, and vote electronically from virtually any location.
• The company is reducing costs by primarily furnishing proxy materials electronically.

Risks

• Stockholders will bear any costs associated with their Internet access.
• The company reserves the right to edit profanity or inappropriate language, or to exclude questions that are not pertinent to meeting matters or that are otherwise inappropriate.
• If a stockholder who has notified the company of their intention to present a proposal at an annual meeting does not appear to present their proposal at such annual meeting, such nomination shall be disregarded and the company is not required to present the proposal for a vote at such annual meeting.

Future Outlook

The company aims to continue its growth trajectory and build a robust pipeline of assets through disciplined capital allocation and strategic business development.

Management Comments

• We believe that a virtual meeting provides expanded access, improved communication and cost savings for our stockholders and Harmony.
• We appreciate your continued support of Harmony.

Industry Context

The move to a virtual annual meeting reflects a broader trend in corporate governance aimed at increasing accessibility and reducing costs. Many companies are adopting virtual or hybrid formats to engage with a wider range of stockholders.

Comparison to Industry Standards

• The director compensation program is designed to be competitive with industry standards, as determined by the Compensation Committee with the assistance of Pay Governance.
• The company's executive compensation program aims to attract, motivate, and retain leaders who can maximize stockholder value, aligning with common objectives in the biopharmaceutical industry.
• The company's corporate governance practices, including the adoption of a Code of Ethics and Conduct Policy and a compensation recovery policy, align with best practices recommended by the SEC and Nasdaq.

Management Changes

Related Party Transactions

• The company is party to a right of use agreement with Paragon, whereby the company has access to and the right to use certain office space leased by Paragon in Chicago, Illinois. For the year ended December 31, 2024, the company incurred fees of $0.3 million pursuant to this agreement.

Stakeholder Impact

• Shareholders are encouraged to participate in the virtual annual meeting to exercise their voting rights.
• The election of directors and ratification of the accounting firm will impact the company's governance and financial oversight.
• Executive compensation decisions are designed to align the interests of executives with those of shareholders.

Next Steps

• Stockholders should review the proxy materials and vote their shares.
• The company will hold the annual meeting on May 15, 2025.
• The company will announce preliminary voting results at the Annual Meeting and disclose voting results on a Current Report on Form 8-K that will be filed with the SEC within four business days after the Annual Meeting.

Key Dates

Keywords

annual meeting, proxy statement, directors, Deloitte & Touche LLP, stockholders, virtual meeting, voting, Harmony Biosciences